R-552 is under clinical development by Eli Lilly and Co and currently in Phase I for Musculoskeletal Inflammation. According to GlobalData, Phase I drugs for Musculoskeletal Inflammation have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how R-552’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
R-552 is under development for the treatment of psoriasis, moderately to severely active rheumatoid arthritis (RA) and joint inflammation. It is administered through the oral route, It targets receptor-interacting protein kinase (RIP1).
Eli Lilly and Co overview
Eli Lilly and Co (Lilly) is a healthcare company that is engaged in the discovery, development, and marketing of human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, immune disorders, men’s health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It also promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company also offers its products in North America, South America, Europe, South Asia, the Middle East, Africa, and North Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
For a complete picture of R-552’s drug-specific PTSR and LoA scores, buy the report here.